Neural and Mobile Assessment OF Behavior Change Among Problem Drinkers


This study will examine the neural mechanisms underlying both spontaneous behavior change and behavior change in response to a brief intervention among problem drinkers.

Study Start Date

February, 27 2018

Estimated Completion Date

February 2022


  • Behavioral: Brief intervention

Study ID

New York State Psychiatric Institute -- 7390



Trial ID


Study Type


Trial Phase


Enrollment Quota



New York State Psychiatric Institute

Inclusion Criteria (Problem Drinkers):
  • Age 21-55
  • English language fluency
  • Strongly right-handed
  • Have an average weekly consumption of greater than 14 standard drinks for women, and greater than 24 standard drinks for men.
  • Current DSM-V mild or moderate alcohol use disorder (AUD) diagnosis Inclusion Criteria (Healthy Controls):
  • Age 21-55
  • English language fluency
  • Strongly right-handed
  • Have an average weekly consumption of less than 7 standard drinks for women and less than 14 standard drinks for men and no heavy drinking days (>4/5 standard drinks for a woman/man)
  • No lifetime diagnosis of AUD

    Exclusion Criteria

    • Past or current severe AUD as defined by DSM
    • V
    • Currently seeking treatment or attempting to stop drinking
    • Past or current alcohol withdrawal symptoms
    • Current DSM-V diagnosis of substance use disorder (other than nicotine or caffeine).
    • Recent use (past month, more than weekly) of recreational drugs.
    • Current or recent (past 5 years) Major Depressive Disorder, Psychotic Disorder, Bipolar
    • Substantial risk of suicide or violence
    • MRI contraindications (e.g., metallic implants, pacemaker, weight > 350 lbs, waist > 55")
    • Hearing impaired/hearing aids, unable to read newspaper at arm's length with corrective
    • Objective cognitive impairment
    • Current or recent (evidence of disease x 5 years) non-skin neoplastic disease or melanoma.
    • Active hepatic disease (not a history of hepatitis) or primary renal disease requiring dialysis, primary untreated endocrine diseases, e.g., Cushing's disease or primary hypothalamic failure or insulin dependent diabetes (Type I or II). Well-treated hypothyroidism will not be excluded.
    • HIV infection
    • Pregnant, lactating (participation allowed 3 months after ceasing lactation), or currently intending to become pregnant
    • Medications that target CNS (e.g., neuroleptics, anticonvulsants, antidepressants, benzodiazepines) within the last month.
    • Any history of ECT
    • Brain disorder such as stroke, tumor, infection, epilepsy, multiple sclerosis, degenerative diseases, head injury (LOC > 5 minutes), mental retardation
    • Diagnosed learning disability, dyslexia, or ADHD
    • For women: Current pregnancy or intention to be pregnant in the near future
  • Gender



    21 Years to 55 Years

    Accepts Healthy Volunteers

    Accepts Healthy Volunteers

    Study Locations and Contact Information (1)

    Study Location Distance Name Phone Email
    NYPInstitute - New York, New York 181.2 miles Nasir H Naqvi MD PhD 212-923-3031 provides clinical trial listings in an easy to view format. All clinical trial information is pulled directly from This website does not guarantee acceptance into any clinical trial, and is not responsible for adverse events that may be incurred from a clinical trial.